Neonatal Respiratory Distress Syndrome Treatment Market Report 2026

Neonatal Respiratory Distress Syndrome Treatment Market Overview

• Neonatal Respiratory Distress Syndrome Treatment market size has reached to $1.03 billion in 2025 • Expected to grow to $1.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: Rising Premature Births Drive Market Growth By Increasing Demand For Treatments That Improve Neonatal Respiratory Outcomes • Market Trend: Advancements In Portable Nitric Oxide Systems Enhance Non-Invasive Respiratory Support In Neonates With Hypoxic Respiratory Failure • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neonatal Respiratory Distress Syndrome Treatment Market?

Neonatal respiratory distress syndrome treatment refers to the management of premature infants with insufficient surfactant production, leading to breathing difficulties. It involves administering exogenous surfactant therapy, providing respiratory support with mechanical ventilation or continuous positive airway pressure (CPAP), and oxygen supplementation. The main types of therapy for neonatal respiratory distress syndrome treatment include oxygen therapy and surfactant therapy. Oxygen therapy involves the administration of oxygen to patients who are unable to obtain sufficient oxygen through normal breathing. It can be administered through parenteral, inhalation, and others and is used by hospitals, sub-acute facilities, home care, and retail pharmacies.

What Is The Neonatal Respiratory Distress Syndrome Treatment Market Growth Forecast?

The neonatal respiratory distress syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $1.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to development of advanced synthetic surfactants, expansion of non-invasive ventilation technologies, rising investment in neonatal care equipment, increasing global awareness of neonatal complications, modernization of hospital respiratory support systems. Major trends in the forecast period include rising adoption of surfactant replacement therapies, increasing use of cpap and non-invasive ventilation, enhanced neonatal intensive care infrastructure, growing focus on premature birth management, rising development of synthetic and bioengineered surfactants.

Global Neonatal Respiratory Distress Syndrome Treatment Market Segmentation

1) By Therapy: Oxygen Therapy, Surfactant Therapy 2) By Route Of Administration: Parenteral, Inhalation, Other Routes Of Administration 3) By End User: Hospitals, Sub-Acute Facilities, Home Care, Retail Pharmacies Subsegments: 1) By Oxygen Therapy: Conventional Oxygen Therapy, High-Flow Nasal Cannula (HFNC) Oxygen Therapy, Continuous Positive Airway Pressure (CPAP) Oxygen Therapy, Invasive Mechanical Ventilation With Oxygen Therapy 2) By Surfactant Therapy: Natural Surfactants, Synthetic Surfactants, Combined Surfactant Therapy (Natural + Synthetic), Prophylactic Surfactant Therapy, Rescue Surfactant Therapy

What Is The Driver Of The Neonatal Respiratory Distress Syndrome Treatment Market?

The rise in incidence of premature births is expected to propel the growth of the neonatal respiratory distress syndrome treatment market going forward. Premature births refer to the delivery of an infant before the completion of thirty-seven weeks of gestation, resulting in underdeveloped organ systems that require specialized medical support. A key factor contributing to the rise in the incidence of premature births is the increasing prevalence of maternal health complications, as such conditions can disrupt normal fetal development and trigger early labor by placing physiological strain on both the mother and the fetus. Neonatal respiratory distress syndrome treatment improves survival outcomes and stabilizes premature infants whose immature lungs render them highly vulnerable to respiratory failure. For instance, in September 2024, according to Statistique Canada, a Canada-based governmental organization, the proportion of births occurring before 37 weeks of gestation increased slightly from 8.2% in 2022 to 8.3% in 2023, indicating a small upward trend in preterm births. Therefore, the rise in incidence of premature births is driving the growth of the neonatal respiratory distress syndrome treatment industry.

Key Players In The Global Neonatal Respiratory Distress Syndrome Treatment Market

Major companies operating in the neonatal respiratory distress syndrome treatment market are Medtronic Plc, GE Healthcare, Koninklijke Philips NV, Drägerwerk AG & Co. KGaA, Chiesi Farmaceutici, Fisher & Paykel Healthcare, Vyaire Medical, Laerdal Medical, Hamilton Medical, Inspiration Healthcare, Ventec Life Systems, Neotech Products, Windtree Therapeutics Inc., Discovery Laboratories Inc., ResMed Inc., Abbott Laboratories, Aerogen Pharma Corp., ONY Biotech, Yuhan Corporation, Atom Medical Corporation, Mindray Bio‑Medical Electronics, Getinge AB, Nihon Kohden Corporation, Siare Engineering Spa

Global Neonatal Respiratory Distress Syndrome Treatment Market Trends and Insights

Major companies operating in the neonatal respiratory distress syndrome treatment market are focusing on developing advanced solutions, such as next-generation, portable nitric-oxide delivery systems, to improve oxygenation, minimize treatment complications, and expand access beyond traditional NICU settings. Portable nitric-oxide systems are medical devices that generate and deliver inhaled nitric oxide on demand, improving oxygenation and alleviating pulmonary hypertension in neonates with hypoxic respiratory failure while enabling safe use during patient transport. For instance, in June 2025, Beyond Air Inc., a US-based medical device company, submitted a PMA supplement to the U.S. Food and Drug Administration for LungFit PH 2, a lighter and transport-ready nitric oxide generator leveraging the company’s patented Ionizer technology. Designed for enhanced portability and convenience, the device maintains continuous nitric oxide delivery while minimizing nitrogen dioxide production, ensuring safer therapy even during neonatal transport. At the same time, phase-4 registry data for INOmax, a well-established iNO therapy by Mallinckrodt, demonstrate continued real-world benefits in neonates with pulmonary hypertension, reinforcing the clinical importance of inhaled nitric oxide in managing hypoxic respiratory failure in newborns.

What Are Latest Mergers And Acquisitions In The Neonatal Respiratory Distress Syndrome Treatment Market?

In January 2024, Chiesi Group, an Italy-based biopharmaceutical company, partnered with Oak Hill Bio to develop neonatal therapies. This collaboration focuses on the development and commercialization of OHB-607, a groundbreaking treatment aimed at preventing severe bronchopulmonary dysplasia (BPD) and its long-term respiratory effects in preterm infants, particularly those born before 28 weeks gestational age with low IGF-1 levels. Oak Hill Bio is a UK-based company developing therapies for neonatal and rare diseases.

Regional Outlook

North America was the largest region in the neonatal respiratory distress syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neonatal Respiratory Distress Syndrome Treatment Market?

The neonatal respiratory distress syndrome treatment market consists of revenues earned by entities by providing services such as surfactant administration services, neonatal respiratory care consulting, telemedicine, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The neonatal respiratory distress syndrome treatment market also includes sales of mechanical ventilators, continuous positive airway pressure (CPAP) machines, high-frequency ventilators, and neonatal incubators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neonatal Respiratory Distress Syndrome Treatment Market Report 2026?

The neonatal respiratory distress syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neonatal respiratory distress syndrome treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.